Bing Han, PhD

Bing Han, PhD

This email address is being protected from spambots. You need JavaScript enabled to view it. | (808) 564-5913

Affiliate Member, University of Hawaiʻi Cancer Center

Academic Appointment(s):
Postdoctor and Junior Researcher, University of Hawaiʻi Cancer Center, University of Hawaiʻi at Mānoa

Degree(s):
PhD, Biomedical Science, Université de Montréal, Montreal, QC, Canada
MD, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Residency and Attending, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zheijiang, China

Research Focus

Dr. Han is studying the influence of RNA processing and alternative splicing in cancer developments. He discovered the molecular mechanism of DBR1 affecting RNA alternative splicing and its potential role in DNA repair. Studying the regulation of FA pathway and its relation with DNA repair and tumorigenesis.

Selected Publications

Han B, Park HK, Ching T, Jayabal P, Wang H, Shen Y, Zhang J, Li L, Garmire L, Fei P. (2017). Human DBR1 Modulates the Recycling of snRNPs to Affect RNA Alternative Splicing and Contributes to the Suppression of Cancer Development. Oncogene advance online publication 15 May 2017; doi:10.1038/onc.2017.150.

Han B, Shen Y, Zhang P, Jayabal P, Che R, Zhang J et al. (2017). Overlooked FANCD2 variant encodes a promising, portent tumor suppressor, and alternative polyadenylation contributes to its expression. Oncotarget, doi: 10.18632/oncotarget.14989.

Han B, Cai H, Chen Y, Hu B, Luo H, Wu Y, Wu J. (2015). The Role of TGFBI (ΒIg-H3) in Gastrointestinal Tract Tumorigenesis. Molecular Cancer, March 2015; 14(1):64.

Han B, Luo H, Raelson J, Huang J, Li Y, Tremblay J, Hu B, Qi S, Wu J. (2014). TGFBI (βIG-H3) Is a Diabetes-Risk Gene Based on Mouse and Human Genetic Studies. Human Molecular Genetics, September 2014; 23(17):4597–4611.

Jayabal P, Pickering A, Han B, Li L, Zheng J, Zhang J, Zhang Y, Fei P. (2014). Basal level of FANCD2 monoubiquitination is required for the maintenance of a sufficient number of licensed-replication origins to fire at a normal rate. Oncotarget, March 2014; 5(5):1326–37.

Publication list via PubMed